Source:http://linkedlifedata.com/resource/pubmed/id/11992548
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0024518,
umls-concept:C0025202,
umls-concept:C0205217,
umls-concept:C0254610,
umls-concept:C0441655,
umls-concept:C0456387,
umls-concept:C0871261,
umls-concept:C1446409,
umls-concept:C1511636,
umls-concept:C1514559,
umls-concept:C1515655,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2349975,
umls-concept:C2911692
|
pubmed:issue |
4
|
pubmed:dateCreated |
2002-5-23
|
pubmed:abstractText |
Interleukin (IL)-15, a pleiotropic cytokine, is involved in the development and maintenance of NK cells and memory CD8+ T cells. We examined the effects of in vivo overexpression of IL-15 on protection against 2 types of murine B16 melanoma lines, MHC class I-negative B16.44 and MHC class I-positive B16F10 cells, using IL-15 transgenic (Tg) mice that we have recently constructed. The tumor growth was severely retarded in IL-15 Tg mice after subcutaneous (s.c.) inoculation with B16.44 or B16F10 cells. IL-15 Tg mice showed an augmented NK cell activity against B16.44 cells, and in vivo depletion of NK cells by anti-asialoGM1 Ab treatment abrogated the antitumor activity in IL-15 Tg mice. On the other hand, IL-15 Tg mice inoculated with B16F10 cells developed a significant level of CTL response against B16F10 cells, and in vivo depletion of CD8+ T cells by anti-CD8 MAb treatment abrogated the antitumor activity. Thus, overexpression of IL-15 augmented antitumor activity against different tumors via augmentation of different antitumor mechanisms. These results suggest a possible therapeutic application of IL-15 for human neoplasms expressing a wide range of MHC class molecules.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2002 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
99
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
573-8
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:11992548-Animals,
pubmed-meshheading:11992548-Antineoplastic Agents,
pubmed-meshheading:11992548-CD4-Positive T-Lymphocytes,
pubmed-meshheading:11992548-CD8-Positive T-Lymphocytes,
pubmed-meshheading:11992548-Genes, MHC Class I,
pubmed-meshheading:11992548-Immunoglobulin G,
pubmed-meshheading:11992548-Interleukin-15,
pubmed-meshheading:11992548-Killer Cells, Natural,
pubmed-meshheading:11992548-Major Histocompatibility Complex,
pubmed-meshheading:11992548-Melanoma,
pubmed-meshheading:11992548-Mice,
pubmed-meshheading:11992548-Mice, Inbred C57BL,
pubmed-meshheading:11992548-Mice, Transgenic,
pubmed-meshheading:11992548-Neoplasms,
pubmed-meshheading:11992548-Spleen,
pubmed-meshheading:11992548-Time Factors,
pubmed-meshheading:11992548-Tumor Cells, Cultured
|
pubmed:year |
2002
|
pubmed:articleTitle |
Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.
|
pubmed:affiliation |
Laboratory of Host Defense and Germfree Life, Research Institute for Disease Mechanism and Control, Nagoya University School of Medicine, Nagoya 466-8550, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|